- Home
- KRON vs BNR Comparison
KRON vs BNR Comparison
Compare KRON & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- BNR
- Stock Information
- Founded
- KRON 2017
- BNR 2014
- Country
- KRON United States
- BNR China
- Employees
- KRON N/A
- BNR N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- BNR Medical Specialities
- Sector
- KRON Health Care
- BNR Health Care
- Exchange
- KRON Nasdaq
- BNR Nasdaq
- Market Cap
- KRON 61.5M
- BNR 69.6M
- IPO Year
- KRON 2020
- BNR 2020
- Fundamental
- Price
- KRON $1.00
- BNR $7.15
- Analyst Decision
- KRON Buy
- BNR
- Analyst Count
- KRON 3
- BNR 0
- Target Price
- KRON $1.63
- BNR N/A
- AVG Volume (30 Days)
- KRON 226.0K
- BNR 6.5K
- Earning Date
- KRON 03-20-2025
- BNR 03-27-2025
- Dividend Yield
- KRON N/A
- BNR N/A
- EPS Growth
- KRON N/A
- BNR N/A
- EPS
- KRON N/A
- BNR N/A
- Revenue
- KRON $9,864,000.00
- BNR $72,832,704.00
- Revenue This Year
- KRON $62.21
- BNR $52.90
- Revenue Next Year
- KRON N/A
- BNR $48.35
- P/E Ratio
- KRON N/A
- BNR N/A
- Revenue Growth
- KRON 146.48
- BNR N/A
- 52 Week Low
- KRON $0.69
- BNR $2.62
- 52 Week High
- KRON $1.60
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- KRON 50.71
- BNR 55.01
- Support Level
- KRON $0.97
- BNR $6.80
- Resistance Level
- KRON $1.03
- BNR $7.29
- Average True Range (ATR)
- KRON 0.05
- BNR 0.55
- MACD
- KRON 0.00
- BNR 0.09
- Stochastic Oscillator
- KRON 65.52
- BNR 67.53
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.